AlphAIAlphAI — Financial news for AI agents
clinicaltrialsarena.comSEP 92 min read

Pharvaris charts approval course for swelling disorder drug on Phase III win

Pharvaris plans to seek US approval for deucrictibant XR after Phase III trial success in treating hereditary angioedema (HAE). The drug showed an 83% reduction in HAE attacks vs. placebo. The company aims to file an NDA in early 2027, facing competition from Takeda's Takhzyro and BioCryst's Orladeyo.

Original reporting
clinicaltrialsarena.com
Published Sep 9, 2026, 11:37 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 9, 2026, 4:09 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefTechnology
Primary signal
MARKET
Neutral
AI market analysis
Mentioned
$PHVS
Relevance
9/10
AlphAI data visualization · based on clinicaltrialsarena.com
Decision brief

The 30-second read

Med
01

Why it matters

The trial data could drive a near-term price rally for Pharvaris and influence valuation of comparable oral HAE therapies.

02

Market read

First report of pivotal Phase III data for a novel oral HAE drug, likely to affect biotech sector sentiment and peer valuations.

03

What to watch

Potential reimbursement challenges and competition from established injectables.

Relevance 9/10Novelty 9/10Timing: upon release

Background

Pharvaris announced positive Phase III results for its oral HAE preventive drug deucrictibant XR and plans an FDA filing in H1 2027.

Market effects

Sector

Positive outlook for HAE oral preventative market, may pressure peers Takeda and BioCryst.

Regional

Boosts Swiss biotech sentiment, modest global biotech ripple.

Global

Adds to overall biotech pipeline optimism, limited macro impact.

Counterpoint

What could challenge this read

Market may have already priced in the data; execution risk if FDA delays.

Key entities

  • Company
    Pharvaris

    Swiss biopharma developing oral HAE therapy.

  • Company
    Takeda

    Current market leader with injectable HAE drug Takhzyro.

  • Company
    BioCryst

    Competes with oral HAE drug Orladeyo.

Read at source← All news

Related articles

SEP 10
$PHVSMedAI 9/10

Pharvaris at Cantor Fitzgerald conference: oral HAE push gains momentum

Pharvaris (PHVS) presented at the Cantor Fitzgerald conference, highlighting 87% reduction in HAE attacks with deucrictibant in Phase III trials. The company plans an on-demand launch in April 2025 and a prophylaxis filing in the first half of 2025. Management addressed safety concerns and outlined a broad commercial strategy. Shares are up 62% over the past year, with analysts setting price targets between $42 and $79.

investing.com3 min
SEP 9
$PHVSHighAI 8/10

Wedbush Reaffirms Outperform Rating On Pharvaris; PT $42 After Positive Phase 3 CHAPTER-3 Data

Wedbush reaffirmed an Outperform rating and $42 price target for Pharvaris (PHVS) after positive Phase 3 data for deucrictibant XR in preventing hereditary angioedema attacks. The study met primary and secondary endpoints, showing an 83% reduction in attack rate. PHVS reported a Q2 2026 net loss of €47.8M and cash of €318M. The stock is up 7.35% on the day.

rttnews.com2 min
SEP 9
$PHVSHighAI 9/10

Pharvaris oral HAE drug cuts attacks by 83% in Phase 3

Pharvaris' oral HAE drug deucrictibant XR reduced attacks by 83% in Phase 3, meeting primary and secondary endpoints. The study enrolled 85 patients across 21 countries. The drug's efficacy is comparable to leading injectable treatments. Pharvaris shares rose 7.35% on the news, and Oppenheimer raised its price target to $75.

european-biotechnology.com2 min